Clinical trials: Filovirus Disease
Marburg Hemorrhagic Fever
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
- Trial name
- NCT01353040
- Testing
- AVI-6003
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Virus Disease
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Background: Ebola virus disease (EVD) is a viral fever that can cause internal bleeding. The death rate from EVD is very high. In a 2014 outbreak in West Africa, 28,000 were affected and 11,000 died.
- Trial name
- NCT05494801
- Where
- Liberia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.
- Trial name
- NCT03161366
- Testing
- rVSVΔG-ZEBOV-GP
- Where
- 2 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Epicentre
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
- Trial name
- NCT02041715
- Testing
- TKM-100802 for Injection
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Ebola Virus Disease
A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
This is a clinical trial in which healthy volunteers will be administered experimental Ebola vaccines. The investigators will vaccinate four groups of volunteers.
- Trial name
- NCT02451891
- Testing
- MVA-EBO Z, ChAd3-EBO Z
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola, Bundibugyo Virus Disease (BVD)
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
The BRAVO study (Bundibugyo: Respondre Avec la Vaccination, "On est ensemble") was developed in response to the 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC).
- Trial name
- BRAVO (NCT07903350)
- Testing
- ERVEBO Vaccination
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Hemorrhagic Fever, Ebola
STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
The 2014 outbreak of Ebola in West Africa is the largest in recorded history with widespread and intense transmission in Guinea, Liberia, and Sierra Leone.
- Trial name
- STRIVE (NCT02378753)
- Testing
- rVSVΔG-ZEBOV
- Where
- 5 sites in Sierra Leone
- Volunteers
- 8,651 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Ebola Virus Disease, Marburg Virus Disease
Evaluating an Ebola and a Marburg Vaccine in Uganda
This study will test two new vaccines, one for Ebola and one for Marburg virus, to see if they are safe, if they have side effects, and if they create an immune response in people who receive them.
- Trial name
- NCT00997607
- Testing
- Ebola vaccine, Marburg vaccine
- Where
- Uganda
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a 2-dose heterologous regimen.
- Trial name
- EBOVAC-Salone (NCT02509494)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- Sierra Leone
- Volunteers
- 1,023 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola
Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
This is a randomized, observer-blind, placebo-controlled trial in male and female subjects ≥18 to <50 years of age. Subjects will be healthy adults based on history, physical examination, and baseline clinical laboratory testing.
- Trial name
- NCT02370589
- Testing
- Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine, 4x Base Dose EBOV GP Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Novavax